Table 2. Knee arthrotomy, synovectomy,... | American Society of Hematology

Table 2.

Knee arthrotomy, synovectomy, and excisional debridement of soft tissue to bone perioperative hemostasis regimen without emicizumab

Time	Single dose	Interval, h
Time	Single dose	3*	4	6	12
Preoperative	rFVIIa 180 μg/kg
POD 0-13		rFVIIa 90 μg/kg and APCC 5000 IU
Preoperative (CVC placement on POD 14)†	rFVIIa 180 μg/kg
POD 0-13		rFVIIa 90 μg/kg and APCC 5000 IU
POD 14-27			rFVIIa 90 μg/kg and APCC 5000 IU
POD 28-41				rFVIIa 90 μg/kg and APCC 5000 IU
POD 42-55‡					rFVIIa 90 μg/kg and APCC 5000 IU

Time	Single dose	Interval, h
Time	Single dose	3*	4	6	12
Preoperative	rFVIIa 180 μg/kg
POD 0-13		rFVIIa 90 μg/kg and APCC 5000 IU
Preoperative (CVC placement on POD 14)†	rFVIIa 180 μg/kg
POD 0-13		rFVIIa 90 μg/kg and APCC 5000 IU
POD 14-27			rFVIIa 90 μg/kg and APCC 5000 IU
POD 28-41				rFVIIa 90 μg/kg and APCC 5000 IU
POD 42-55‡					rFVIIa 90 μg/kg and APCC 5000 IU

CVC, central venous catheter.

Interval describes duration between alternating rFVIIa and APCC therapy (ie, rFVIIa alternating with APCC every 3 hours).

On POD 14, CVC placement was necessary, so tapering regimen was restarted.

After POD 55, regular bypassing agent prophylaxis regimen was resumed.